Which has higher earnings & valuation, AGMB or CBUS?

AgomAb Therapeutics has higher earnings, but lower revenue than Cibus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Cibus $3.64M 33.34 -$127.08M -$1.65 N/A

Does the media refer more to AGMB or CBUS?

In the previous week, AgomAb Therapeutics had 4 more articles in the media than Cibus. MarketBeat recorded 6 mentions for AgomAb Therapeutics and 2 mentions for Cibus. Cibus' average media sentiment score of 0.93 beat AgomAb Therapeutics' score of 0.37 indicating that Cibus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cibus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EIKN or CBUS more profitable?

Eikon Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Eikon Therapeutics' return on equity of 0.00% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Cibus -2,258.89% -287.03% -27.99%

Does the media favor EIKN or CBUS?

In the previous week, Eikon Therapeutics had 7 more articles in the media than Cibus. MarketBeat recorded 9 mentions for Eikon Therapeutics and 2 mentions for Cibus. Eikon Therapeutics' average media sentiment score of 1.05 beat Cibus' score of 0.93 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cibus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CABA or CBUS?

Cibus has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Cibus $3.64M 33.34 -$127.08M -$1.65 N/A

Is CABA or CBUS more profitable?

Cabaletta Bio has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Cabaletta Bio's return on equity of -128.27% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Cibus -2,258.89% -287.03% -27.99%

Does the media prefer CABA or CBUS?

In the previous week, Cabaletta Bio had 5 more articles in the media than Cibus. MarketBeat recorded 7 mentions for Cabaletta Bio and 2 mentions for Cibus. Cabaletta Bio's average media sentiment score of 1.08 beat Cibus' score of 0.93 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cibus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CBUS or PRTA?

Cibus has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cibus $3.64M 33.34 -$127.08M -$1.65 N/A Prothena $9.68M 48.21 -$244.09M -$0.84 N/A

Is CBUS or PRTA more profitable?

Prothena has a net margin of -80.68% compared to Cibus' net margin of -2,258.89%. Prothena's return on equity of -16.45% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,258.89% -287.03% -27.99% Prothena -80.68% -16.45% -14.51%

Does the media prefer CBUS or PRTA?

In the previous week, Cibus and Cibus both had 2 articles in the media. Cibus' average media sentiment score of 0.93 equaled Prothena'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cibus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, CBUS or PBYI?

Puma Biotechnology has higher revenue and earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cibus $3.64M 33.34 -$127.08M -$1.65 N/A Puma Biotechnology $231.24M 2.05 $31.11M $0.52 17.63

Is CBUS or PBYI more profitable?

Puma Biotechnology has a net margin of 11.50% compared to Cibus' net margin of -2,258.89%. Puma Biotechnology's return on equity of 20.76% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,258.89% -287.03% -27.99% Puma Biotechnology 11.50% 20.76% 13.22%

Does the media refer more to CBUS or PBYI?

In the previous week, Puma Biotechnology had 2 more articles in the media than Cibus. MarketBeat recorded 4 mentions for Puma Biotechnology and 2 mentions for Cibus. Puma Biotechnology's average media sentiment score of 1.05 beat Cibus' score of 0.93 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cibus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cibus (CBUS) Competitors

$1.59 +0.02 (+1.15%)

As of 12:06 PM Eastern

Compare

CBUS vs. AGMB, EIKN, CABA, PRTA, and PBYI

Should you buy Cibus stock or one of its competitors? Cibus's main competitors and comparable companies include AgomAb Therapeutics (AGMB), Eikon Therapeutics (EIKN), Cabaletta Bio (CABA), Prothena (PRTA), and Puma Biotechnology (PBYI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cibus compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

AgomAb Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. AgomAb Therapeutics' return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Cibus	-2,258.89%	-287.03%	-27.99%

AgomAb Therapeutics has higher earnings, but lower revenue than Cibus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Cibus	$3.64M	33.34	-$127.08M	-$1.65	N/A

In the previous week, AgomAb Therapeutics had 4 more articles in the media than Cibus. MarketBeat recorded 6 mentions for AgomAb Therapeutics and 2 mentions for Cibus. Cibus' average media sentiment score of 0.93 beat AgomAb Therapeutics' score of 0.37 indicating that Cibus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cibus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

33.8% of Cibus shares are owned by institutional investors. 29.9% of Cibus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AgomAb Therapeutics presently has a consensus price target of $37.50, suggesting a potential upside of 182.70%. Cibus has a consensus price target of $9.00, suggesting a potential upside of 466.75%. Given Cibus' higher possible upside, analysts clearly believe Cibus is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

AgomAb Therapeutics beats Cibus on 7 of the 12 factors compared between the two stocks.

How does Cibus compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Eikon Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Eikon Therapeutics' return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Cibus	-2,258.89%	-287.03%	-27.99%

33.8% of Cibus shares are held by institutional investors. 29.9% of Cibus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Eikon Therapeutics had 7 more articles in the media than Cibus. MarketBeat recorded 9 mentions for Eikon Therapeutics and 2 mentions for Cibus. Eikon Therapeutics' average media sentiment score of 1.05 beat Cibus' score of 0.93 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cibus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cibus has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
Cibus	$3.64M	33.34	-$127.08M	-$1.65	N/A

Eikon Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 172.03%. Cibus has a consensus price target of $9.00, suggesting a potential upside of 466.75%. Given Cibus' higher probable upside, analysts plainly believe Cibus is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Eikon Therapeutics beats Cibus on 8 of the 15 factors compared between the two stocks.

How does Cibus compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Cibus has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Cibus	$3.64M	33.34	-$127.08M	-$1.65	N/A

Cabaletta Bio has a beta of 3.27, meaning that its stock price is 227% more volatile than the broader market. Comparatively, Cibus has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

33.8% of Cibus shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by company insiders. Comparatively, 29.9% of Cibus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cabaletta Bio has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Cabaletta Bio's return on equity of -128.27% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Cibus	-2,258.89%	-287.03%	-27.99%

In the previous week, Cabaletta Bio had 5 more articles in the media than Cibus. MarketBeat recorded 7 mentions for Cabaletta Bio and 2 mentions for Cibus. Cabaletta Bio's average media sentiment score of 1.08 beat Cibus' score of 0.93 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cibus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio currently has a consensus price target of $15.33, indicating a potential upside of 410.26%. Cibus has a consensus price target of $9.00, indicating a potential upside of 466.75%. Given Cibus' higher probable upside, analysts clearly believe Cibus is more favorable than Cabaletta Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cabaletta Bio beats Cibus on 9 of the 16 factors compared between the two stocks.

How does Cibus compare to Prothena?

Cibus (NASDAQ:CBUS) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Cibus currently has a consensus price target of $9.00, suggesting a potential upside of 466.75%. Prothena has a consensus price target of $24.57, suggesting a potential upside of 175.62%. Given Cibus' higher probable upside, research analysts clearly believe Cibus is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Cibus has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Prothena has a beta of -0.33, suggesting that its share price is 133% less volatile than the broader market.

Cibus has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	33.34	-$127.08M	-$1.65	N/A
Prothena	$9.68M	48.21	-$244.09M	-$0.84	N/A

Prothena has a net margin of -80.68% compared to Cibus' net margin of -2,258.89%. Prothena's return on equity of -16.45% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Prothena	-80.68%	-16.45%	-14.51%

33.8% of Cibus shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 29.9% of Cibus shares are held by company insiders. Comparatively, 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cibus and Cibus both had 2 articles in the media. Cibus' average media sentiment score of 0.93 equaled Prothena'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cibus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prothena beats Cibus on 10 of the 15 factors compared between the two stocks.

How does Cibus compare to Puma Biotechnology?

Cibus (NASDAQ:CBUS) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

33.8% of Cibus shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 29.9% of Cibus shares are owned by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cibus presently has a consensus price target of $9.00, indicating a potential upside of 466.75%. Puma Biotechnology has a consensus price target of $6.00, indicating a potential downside of 34.57%. Given Cibus' higher probable upside, equities analysts clearly believe Cibus is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has higher revenue and earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	33.34	-$127.08M	-$1.65	N/A
Puma Biotechnology	$231.24M	2.05	$31.11M	$0.52	17.63

Cibus has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

In the previous week, Puma Biotechnology had 2 more articles in the media than Cibus. MarketBeat recorded 4 mentions for Puma Biotechnology and 2 mentions for Cibus. Puma Biotechnology's average media sentiment score of 1.05 beat Cibus' score of 0.93 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cibus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has a net margin of 11.50% compared to Cibus' net margin of -2,258.89%. Puma Biotechnology's return on equity of 20.76% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Puma Biotechnology	11.50%	20.76%	13.22%

Summary

Puma Biotechnology beats Cibus on 10 of the 15 factors compared between the two stocks.

Get Cibus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBUS vs. The Competition

Export

Metric	Cibus	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$121.14M	$3.89B	$7.21B	$12.75B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-0.96	14.90	274.47	25.48
Price / Sales	33.34	1,414.37	637.09	88.51
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	3.97	15.16	10.38	6.26
Net Income	-$127.08M	-$22.82M	$3.49B	$358.19M
7 Day Performance	-0.13%	-1.72%	-2.11%	-1.31%
1 Month Performance	-10.28%	2.31%	0.52%	-2.59%
1 Year Performance	16.76%	43.26%	24.69%	8.65%

Cibus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBUS Cibus	1.6081 of 5 stars	$1.59 +1.1%	$9.00 +466.8%	+15.4%	$121.14M	$3.64M	N/A	48
AGMB AgomAb Therapeutics	3.597 of 5 stars	$13.46 -3.5%	$37.50 +178.7%	N/A	$487.61M	N/A	N/A	62
EIKN Eikon Therapeutics	3.3419 of 5 stars	$8.87 -3.7%	$25.00 +181.8%	N/A	$479.95M	N/A	N/A	384	Positive News
CABA Cabaletta Bio	3.0825 of 5 stars	$2.77 +0.9%	$15.33 +454.6%	+48.4%	$470.47M	N/A	N/A	50	Positive News Analyst Downgrade
PRTA Prothena	3.1302 of 5 stars	$8.94 -0.9%	$24.57 +175.0%	+8.8%	$468.01M	$9.68M	N/A	130	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBUS) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cibus (CBUS) Competitors

CBUS vs. AGMB, EIKN, CABA, PRTA, and PBYI

How does Cibus compare to AgomAb Therapeutics?

Summary

How does Cibus compare to Eikon Therapeutics?

Summary

How does Cibus compare to Cabaletta Bio?

Summary

How does Cibus compare to Prothena?

Summary

How does Cibus compare to Puma Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBUS vs. The Competition

Cibus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cibus (CBUS) Competitors

CBUS vs. AGMB, EIKN, CABA, PRTA, and PBYI

How does Cibus compare to AgomAb Therapeutics?

Is AGMB or CBUS more profitable?

Which has higher earnings & valuation, AGMB or CBUS?

Does the media refer more to AGMB or CBUS?

Do insiders & institutionals hold more shares of AGMB or CBUS?

Do analysts rate AGMB or CBUS?

Summary

How does Cibus compare to Eikon Therapeutics?

Is EIKN or CBUS more profitable?

Do institutionals & insiders have more ownership in EIKN or CBUS?

Does the media favor EIKN or CBUS?

Which has preferable earnings & valuation, EIKN or CBUS?

Do analysts prefer EIKN or CBUS?

Summary

How does Cibus compare to Cabaletta Bio?

Which has stronger valuation & earnings, CABA or CBUS?

Which has more volatility & risk, CABA or CBUS?

Do institutionals and insiders believe in CABA or CBUS?

Is CABA or CBUS more profitable?

Does the media prefer CABA or CBUS?

Do analysts recommend CABA or CBUS?

Summary

How does Cibus compare to Prothena?

Do analysts prefer CBUS or PRTA?

Which has more volatility and risk, CBUS or PRTA?

Which has preferable valuation & earnings, CBUS or PRTA?

Is CBUS or PRTA more profitable?

Do insiders & institutionals hold more shares of CBUS or PRTA?

Does the media prefer CBUS or PRTA?

Summary

How does Cibus compare to Puma Biotechnology?

Do institutionals and insiders believe in CBUS or PBYI?

Do analysts recommend CBUS or PBYI?

Which has higher earnings and valuation, CBUS or PBYI?

Which has more volatility & risk, CBUS or PBYI?

Does the media refer more to CBUS or PBYI?

Is CBUS or PBYI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBUS vs. The Competition

Cibus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools